Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Advanced Chronic Kidney Disease
Table 2
Secondary outcomes.
Total n = 48
Warfarin n = 33/39
DOAC n = 15/17
value
Thromboembolic event at 3 months
3 (6)
3 (6)
0 (0)
0.542
DVT Ischemic stroke
2 (67) 1 (33)
2 (67) 1 (33)
0 (0) 0 (0)
1.000 1.000
Median time to event, days Median time to any thromboembolic event, median, IQR DVT, median, IQR Ischemic stroke, median, IQR
26 (25,26) 26 (25,41) 37 (37,37)
26 (25,26) 26 (25,41) 37 (37,37)
0 (0,0) 0 (0,0) 0 (0,0)
— — —
Bleed at 3 months
10 (21)
7 (21)
3 (20)
1.000
Major nonsurgical
3 (6)
2 (29)
1 (33)
1.000
Clinically relevant nonmajor
5 (10)
4 (57)
1 (33)
1.000
Minor
2 (4)
1 (14)
1 (33)
0.519
Median time to event, days
Median time to any bleed, median, IQR
38 (9,63)
37 (4,58)
38 (11,38)
0.667
Major nonsurgical, median, IQR
48 (12,82)
31 (3,58)
90 (90,90)
1.000
Clinically relevant nonmajor, median, IQR
25 (9,71)
25 (4,48)
11 (11,11)
0.800
Minor, median, IQR
83 (76,83)
76 (76,76)
38 (38,38)
1.000
All data presented as n (%) unless otherwise stated: 1 patient in the warfarin group experienced a hemorrhagic stroke which occurred at 161 days from AC, 1 patient experienced a clinically relevant nonmajor bleeding after 90 days (139) in the warfarin group, 6 patients were lost to follow-up at 3 months in the warfarin arm, and 2 patients were lost to follow-up in the DOAC arm.
